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PURPOSE. The induction of proinsulin expression by transgenesis or intramuscular gene
therapy has been shown previously to retard retinal degeneration in mouse and rat models of
retinitis pigmentosa (RP), a group of inherited conditions that result in visual impairment. We
investigated whether intraocular treatment with biodegradable poly (lactic-co-glycolic) acid
microspheres (PLGA-MS) loaded with proinsulin has cellular and functional neuroprotective
effects in the retina.
METHODS. Experiments were performed using the Pde6brd10 mouse model of RP.
Methionylated human recombinant proinsulin (hPI) was formulated in PLGA-MS, which
were administered by intravitreal injection on postnatal days (P) 14 to 15. Retinal
neuroprotection was assessed at P25 by electroretinography, and by evaluating outer nuclear
layer (ONL) cellular preservation. The attenuation of photoreceptor cell death by hPI was
determined by TUNEL assay in cultured P22 retinas, as well as Akt phosphorylation by
immunoblotting.
RESULTS. We successfully formulated hPI PLGA-MS to deliver the active molecule for several
weeks in vitro. The amplitude of b-cone and mixed b-waves in electroretinographic recording
was significantly higher in eyes injected with hPI-PLGA-MS compared to control eyes.
Treatment with hPI-PLGA-MS attenuated photoreceptor cell loss, as revealed by comparing
ONL thickness and the number of cell rows in this layer in treated versus untreated retinas.
Finally, hPI prevented photoreceptor cell death and increased AktThr308 phosphorylation in
organotypic cultured retinas.
CONCLUSIONS. Retinal degeneration in the rd10 mouse was slowed by a single intravitreal
injection of hPI-PLGA-MS. Human recombinant proinsulin elicited a rapid and effective
neuroprotective effect when administered in biodegradable microspheres, which may
constitute a future potentially feasible delivery method for proinsulin-based treatment of RP.
Keywords: retinitis pigmentosa, neuroprotection, photoreceptors
Inherited retinal dystrophies, including retinitis pigmentosa(RP), are a large group of diseases in which over 250 genes
and loci have been implicated (available in the public domain at
http://www.sph.uth.tmc.edu/Retnet/disease.htm). This genetic
diversity underscores the need to develop alternative thera-
peutic approaches to attenuate disease progression while gene
therapies are developed and optimized. Numerous gene
mutations associated with RP, as well as other retinal
dystrophies, have been shown to induce photoreceptor cell
death, leading to progressive loss of visual function.1–4 Among
other RP models, this pathologic process has been widely
studied in the rd10 mouse, which carries an autosomal
recessive, missense mutation in the Pde6b gene.1,5 The disease
course in this model6,7 allows for evaluation of experimental
treatments by electroretinographic and histologic analysis.
Promoting cell survival is a plausible strategy for the
treatment of various retinal dystrophies. Over 2 decades ago,
Faktorovitch et al.8 first proposed that growth factors could be
used to treat retinal degenerative diseases. Of the many factors
tested in initial studies, in which the ability to rescue
photoreceptors from the damaging effect of light was assessed,
seven showed promise, including fibroblast growth factor
(FGF), human ciliary neurotrophic factor (CNTF), and insulin-
like growth factor II (IGF-II).9 Subsequent studies investigated
the use of peptides and growth factors in different animal
models of eye diseases, including neurotrophins 3 and 4, and
brain-derived neurotrophic factor (BDNF),10 and attempted to
identify appropriate minimally invasive and controlled drug
delivery systems.11–16 Compounds extensively tested include
glial cell-derived neurotrophic factor (GDNF),17 CNTF,18 and,
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more recently, rod-derived cone viability factor (RdCVF).19
Interestingly, the steroid sex hormone progesterone also has
been identified as a promising candidate to decrease cell death
in the rd1 mouse model.20 Research has begun to unravel the
antiapoptotic mechanism of progesterone action, which
appears to involve the progesterone receptor membrane
component 1 (PGRMC1), the expression of which is upregu-
lated in the degenerating rd10 mouse retina.21
Proinsulin and insulin also have shown their neuroprotec-
tive effect in several models of RP.22–24 Long considered a mere
low-activity precursor of pancreatic insulin, proinsulin is
produced locally by several tissues outside the pancreas, and
has been shown to significantly attenuate cell death during
neural development (see review25–28). The therapeutic poten-
tial of human proinsulin (hPI) has been demonstrated in
studies that have systemically increased hPI levels. In the rd10
mouse, low-level constitutive transgenic expression of hPI in
muscle attenuates vision loss and delays photoreceptor cell
death.22 However, the use of this procedure in a clinical setting
is not feasible. In the P23H rat model of autosomal dominant
RP, hPI administered by intramuscular injection of adenoasso-
ciated viral vector, pseudotype 1 (AAV1), which is suitable for
gene therapy in humans, preserves the structure and function
of cones and rods, as well with their contacts with
postsynaptic neurons.24
Although systemic gene therapy is feasible in human
patients, a more convenient strategy for RP therapy is local
administration close to the affected cells, which would allow
sustained delivery in animal models and eventually could be
applied to patients. Biocompatible, biodegradable poly (lactic-
co-glycolic acid) microspheres (PLGA-MS) disappear after
releasing the drug contained within, and are well tolerated
following intravitreal injection in animals and humans.29,30 The
primary objective of the present study was to manufacture a
suitable hPI-PLGA-MS formulation that could gradually deliver
an appropriate concentration of the active molecule. Next, we
set out to assess the neuroprotective effect of this formulation
in vivo in the rd10 mouse, when injected before the onset of
massive photoreceptor cell death. To further examine the
direct antiapoptotic effects of hPI on retina cells, we studied
the changes in TUNEL staining and AktThr308 phosphorylation
after hPI treatment in retinal explants from rd10 mice.
MATERIALS AND METHODS
Animals
The rd10 mouse model of retinal degeneration is a homozy-
gous mutant for phosphodiesterase 6b (Pde6brd10/rd10) on a
C57BL/6J background. It was kindly provided by Bo Chang
from The Jackson Laboratory (Bar Harbor, ME, USA). All
animals were housed and handled in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, European Union guidelines, and those of the
local ethics committees of the CSIC and the Comunidad de
Madrid. Mice were bred in the CIB core facilities on a 12/12-
hour light/dark cycle.
PLGA Microsphere Formulation
Methionylated hPI, Batch F148510 2 1-1, was manufactured by
Biotecnol Limited (Hertfordshire, UK) and PLGA-MS were
manufactured by ProRetina Therapeutics S.L. (Noain, Spain).
The hPI was encapsulated in microspheres at a concentration of
3.2 lg hPI/mg PLGA-MS, equivalent to 22.4 lg hPI/mL of injected
material (7 mg PLGA-MS/mL). As a control, empty PLGA-MS (7
mg/mL) were injected. The vehicle used for experimental and
control materials was 4% (wt/vol) mannitol, 1% (wt/vol) Tween-
20, and 1% (wt/vol) carboxymethylcellulose.
Microsphere Fabrication Procedure
We generated PLGA-MS from a W1/O/W2 emulsion at room
temperature and normal atmospheric pressure using the solvent
evaporation technique, in a modified version of the method of
Mao et al.31 Dichloromethane (1.5 mL) was added to a test tube
containing 200 mg RG503H polymer (Resomer RG 503H; Mat.
Nr.: 719870; Boehringer Ingelheim, Germany). Once the oil phase
was formed (O þ polymer), 300 lL of aqueous phase (W1 þ 5
mg/mL hPI) was added slowly, drop by drop, to avoid the
formation of large drops in the oil phase. The mixture was
homogenized for 1 minute and 2 mL of 2.5% (wt/vol) PVA (W2)
aqueous solution was added to the vial. The contents were stirred
again at low speed for 1 minute with an UltraTurrax T25
homogenizer (IKA, Staufen, Germany). The resulting W1/O/W2
emulsion was stirred for 3 hours at room temperature and normal
atmospheric pressure to evaporate the organic solvent. The
microspheres were washed with 900 mL of cold Milli-Q water
(Merck Millipore Corporation, Billerica, MA, USA) to remove PVA
from the solution and were collected over a 1-lm mesh, and
gathered using a spatula. The microsphere preparation was
frozen for 24 hours at808C and finally lyophilized for 24 hours.
Microspheres were examined for particle size distribution by laser
light scattering using a Coulter LS32 (Beckman Coulter, Inc., Brea,
CA, USA). Particles (40 mg) then were suspended in distilled
water and particle size calculated by Fraunhofer approximation.
Intravitreal Injection
Male and female mice of at least 5 g bodyweight were treated at
postnatal day (P) 14 or 15. Animals were anesthetized with an
intraperitoneal (IP) injection of a ketamine (95 mg/kg)þxylazine
(5 mg/kg) mixture, diluted in 0.9% (wt/vol) NaCl. A Hamilton
syringe (Hamilton Robotics, Bonaduz, Switzerland) with a 33-
gauge (G) needle was used to intravitreally inject a single 1-ll
volume of a sterile preparation of hPI-PLGA-MS (22.4 ng dose in
the case of FP50) into the right eye, or an equivalent volume of
control (empty) PLGA-MS into the left eye. Tobramycin (Tobrex)
was applied to the eye after injection to protect the cornea and
prevent infection. Electroretinographic (ERG) recordings were
performed at P25. Animals then were euthanized and retinas and
serum samples collected.
ERG Recording
Mice were handled and ERG recordings performed as
described previously.22 Measurements were performed by an
observer blind to the experimental condition of the animal.
Electroretinographic signals were amplified and band filtered
between 0.3 and 1000 Hz (CP511 Preamplifier; Grass
Instruments, Quincy, MA, USA) and digitized to 10 kHz using
a PowerLab acquisition data card (AD Instruments Ltd.,
Oxfordshire, UK). Graphic representations of the signals
recorded and the luminous stimuli control were performed
with the Scope v6.4 PowerLab software. Electroretinographic
wave amplitudes were measured off-line and the results
averaged. Wave amplitude analysis was performed using the
MATLAB (Mathworks, Natick, MA, USA) application.
Histology and Cell Counting
Animals were euthanized, the dorsal part of the eyeball was
marked with a red label to allow orientation and then the eyes
were enucleated. Eyes were fixed for 2 hours in 4% (wt/vol)
paraformaldehyde in PBS, and then cryoprotected by incuba-
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tion in increasing concentrations of sucrose (10%, 20%, 30%,
and 40% [wt/vol] in PBS). The eyes then were embedded in
Tissue-Tek (Sakura Finetec, Torrance, CA, USA), and frozen on
dry ice. Cryostat sections (5 lm) were mounted on poly-lysine-
coated glass slides, dried at room temperature, fixed for 15
minutes with 4% (wt/vol) paraformaldehyde in PBS, and
coverslipped with Fluoroshield containing 40,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich Corp., St. Louis, MO, USA)
to counterstain the nuclei. Five lm equatorial (horizontal)
sections in which optic nerve appeared were collected (the
total number of sections were 20–25). Since the microinjection
procedure was performed in the dorsal region, we avoided this
area for quantification purposes.
Five sections per retina were analyzed. For each section,
one photograph was taken for each of the six retinal zones
defined as T1, T2, T3, T4, T5, and T6 along the nasotemporal
retinal axis. In the nasal region, T1 was located at 100 lm from
the ora serrata; T3, 100 lm from the optic nerve; and T2
equidistant from T1 and T3. The same procedure was followed
in the temporal region, taking photographs T4, T5, and T6
from the optic nerve to the ora serrata.
In each photo, measurements were performed in triplicate to
obtain an average value per retinal zone per section. The
following parameters were measured using ImageJ v1.44p
software (available in the public domain at https://imagej.nih.
gov/ij; National Institutes of Health [NIH], Bethesda, MD, USA):
outer nuclear layer (ONL) thickness (using the ‘‘freehand line’’
and ‘‘measure’’ tools) and number of rows in the ONL (by
visually counting the nuclei). The raw data acquired were
exported and pixel values for ONL thickness were converted to
lm using the appropriate equivalence for the microscope used.
Statistical Analysis
The statistical analysis of histologic and ERG data was
performed by independent observers. Repeated measurements
for each of the six retinal regions defined for histologic
evaluation were validated using the Hotelling t-test to identify
artifacts. For histologic data, the values obtained for hPI-PLGA-
MS–treated and control eyes were compared using a Student’s
t-test for paired samples. For ERG data, differences in wave
amplitudes between treated and control eyes were assessed by
repeated measures analysis and Student’s t-test used for
comparison. Significance was established at P < 0.05.
Measurement of Proinsulin Concentration
The concentration of hPI was measured in PLGA-MS superna-
tants and in mouse serum samples and retinal extracts. For the
analysis of supernatant and serum samples, 20-ll volumes were
assayed in duplicate. Retinal extracts were prepared by
homogenizing one retina in 60 lL of RIPA buffer (50 mM
NaH2PO4.H20, 100 mM Na2HPO4.7H20, 100 mM NaCl, 0.1% [wt/
vol] Triton X-100, and protease inhibitors) and assaying 20-ll
samples in duplicate. The total protein content of retinal extracts
was determined by Bradford assay. Human proinsulin levels were
measured using the Human Total Proinsulin ELISA kit (EZHPI-
15K; Merck Millipore) according to the manufacturer’s instruc-
tions. Plates were read using a microplate reader set to dual
wavelength measurement at 450 nm with a background
correction set at 590 nm. Absorbance data were analyzed using
MasterPlex 2010 software (Merlin Equipment Ltd., Dorset, UK).
Picomolar concentrations extrapolated from the standard curve
were assessed using the acceptance criteria recommended by
the manufacturer. In addition, a prevalidation study was
performed using the retinal extract as the matrix, in which
values were classified as follows: <10 pM, nondetectable; 10 to
20 pM, detectable but not quantifiable;>20 pM, quantifiable. For
serum samples hPI levels were expressed in pM. For retina
samples, detectable values were expressed as pmol per gram of
total protein or as fmol per retina.
Whole Mount Retinal Cultures
Retinas were dissected from P22 rd10 mice and retinal
explants were cultured free-floating in M24 multiwell plates
for 24 hours in 1.2 mL Dulbecco’s modified Eagle’s medium
(DMEM)/F12 medium containing N2-supplement, but without
insulin and, where indicated, containing 108 M hPI. Retinas
were subsequently fixed in 4% (wt/vol) paraformaldehyde in
PBS for 1 hour at RT and processed for detection of cell death.
Cell Death Visualization and Counting
Photoreceptor cell death was visualized by DNA fragmentation
assay terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (DeadEnd FluorometricTUNEL system; Promega,
Madison, WI, USA), as described previously.22 After labeling, the
retinas were flat-mounted in Fluoromount-G (Southern Biotech-
nology, Birmingham, AL, USA), stained with DAPI, and analyzed
on a laser confocal microscope (TCS SP5; Leica, Microsystems,
Wetzlar, Germany). Image acquisition was performed in 4 areas
of each retina. Serial optical sections were acquired in the depth
of the ONL, as determined in retinal sections, to ensure that
TUNEL-positive nuclei belong to photoreceptors. Direct count-
ing of TUNEL-positive cells was done on merged images using
ImageJ v1.48.s software. Paired statistical analysis was per-
formed using the Wilcoxon signed-rank test.
Immunoblots
Retinas were cultured as indicated above for a 3-hour period
without insulin or proinsulin and then hPI (108 M) was added
to the group of treated retinas, maintaining the culture for
additional 2, 5, or 15 minutes. Total Akt protein and phospho-
AktThr308 levels were determined by immunoblot. Protein
extraction was done by sonication of the retinas in RIPA lysis
buffer (containing 2 mM Na3VO4, 10 mM NaF, and 4 mM Na
Pirophosphate as phosphatase inhibitors), maintaining the
tubes 30 minutes on ice. Then, 15 lg protein of each sample
were fractionated by precast 10% to 12% (wt/vol) sodium
dodecyl sulfate (SDS)–polyacrylamide gel (Criterion TGX, Bio-
Rad, Munich, Germany) electrophoresis, and proteins were
transferred to polyvinylidine fluoride (PVDF) membranes using
a Trans-Blot Turbo system (Bio-Rad Laboratories, Hercules, CA,
USA). Blots were incubated with rabbit polyclonal anti-
pAktThr308 (1:1000; Cell Signaling, Beverly, MA, USA) and
developed with the appropriate peroxidase-conjugated sec-
ondary antibody (1:20,000) using the Pierce ECL Western
Blotting Substrate. After striping the membrane was incubated
with rabbit polyclonal anti-Akt1 (1:1000; Cell Signaling) and
developed as indicated above. Films were scanned and images
were analyzed using the ImageJ v1.48.s program.
RESULTS
Release Profile of Human Proinsulin From PLGA
Microspheres
To assess the efficacy of a sustained-release hPI formulation as a
neuroprotective therapy in the rd10 mouse, we first formulated
the protein in PLGA microspheres. A number of different hPI
preparations encapsulated in PGLA-MS were developed and
characterized to evaluate a wide range of release parameters,
including initial burst, progressive release, and release interval.
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The quality of the PLGA-MS was screened by scanning
electron microscopy to assess particle size and surface
characteristics. A typical pellet of PLGA-MS (Fig. 1A) included
particles with a smooth surface, 10 to 32 lm in diameter, which
is an adequate size for intravitreal injection. The hPI release
profile varied among batches, particularly in terms of initial
burst. Two different profiles, displaying a low and a high initial
burst of release, are shown in Figure 1B. Due to the rapid
progression of retinal degeneration in the rd10 mouse model,
we selected the FP50 formulation for the study; this formulation
was characterized by a high initial burst, which was likely to
ensure a therapeutic concentration within 24 hours of injection,
as well as continuous in vitro release of hPI for at least 45 days.
The FP50 formulation used in the present study contained
22.42 lg hPI/mL of injected preparation. Male and female rd10
mice at P14 or P15 (i.e., before the onset of any detectable
photoreceptor death) were injected with 1 lL of FP50 in the
right eye (treated) and 1 lL of empty PLGA-MS from the same
batch in the left eye (control). Analysis of hPI concentration in
extracts taken from treated retinas at P25 (n ¼ 17) revealed
considerable variation in in vivo hPI release, with values
ranging from undetectable to 203 pmol/g of total protein, with
most values in the range of 16 to 32 pmol/g. In control retinas,
as well as in the serum, hPI always was undetectable. These
results demonstrated that relatively low levels of hPI released
from the intravitreal MS did reach the target tissue without
systemic dissemination.
Photoreceptor Preservation in the rd10 Mouse
After Intravitreal Injection of hPI-PLGA-MS
Histologic evaluation of the rd10 retina at P25, by which time
massive photoreceptor loss has occurred, revealed photore-
ceptor preservation in hPI-PLGA-MS–treated eyes with respect
to control eyes, at least in some areas (Fig. 2). The average
thickness of the ONL in treated retinas was greater than that
measured in control retinas in all regions (Fig. 2B), with
significant differences observed in T1 (nasal) and T3 and T4
(central) retinal regions. The number of photoreceptor rows
also was higher in retinas treated with hPI-PLGA-MS com-
pared to contralateral control retinas (Fig. 2C), with signifi-
FIGURE 1. Morphology and protein release properties of hPI-PLGA
microspheres. (A) Scanning electron microscopy microphotography of
a pellet containing microspheres of different sizes. The diameter of
several microspheres is indicated. The inset shows a single enlarged
microsphere. (B) Cumulative release of hPI in vitro from two
formulations (FP16 and FP50) for up to 45 days. The percentage of
the total load released was calculated by measuring hPI levels in the
medium. Note that the x-axis is not a linear scale.
FIGURE 2. Attenuation of photoreceptor cell loss in the rd10 mouse
retina after hPI treatment. Retinal sections from control and treated
eyes were processed at P25. (A) Representative images of DAPI-stained
retinal sections from control (Control-MS) and treated (hPI-MS) retinas
of the same animal. Images were taken from nasal regions,
approximately equidistant between the optic nerve and the ora serrata
(T2). The ONL, inner nuclear layer (INL) and retinal ganglion cells
(RGC) are indicated. (B) After DAPI staining, ONL thickness was
measured in 6 regions of the retina, in nasotemporal sequence (T1–
T6), in equatorial sections (see Methods). (C) The number of cell rows
in the ONL, which corresponds to photoreceptors, was scored in DAPI-
stained retina sections, as described in (B). Plots show the mean (6
SEM) values for control (Control-MS) and hPI-treated (hPI-MS) retinas. n
¼ 11 mice, 5 sections per retina, 3 measurements per region and
section; O.N., optic nerve. *P < 0.05. Scale bar: 15 lm.
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cant differences observed in the nasal T1 region and close to
the optic nerve (T3). That the effect of hPI was more marked
in the nasal retina concurs with previous findings in the P23H
rat model.24 There was no significant difference in the INL
thickness in retinas treated with hPI-PLGA-MS compared to
contralateral control retinas.
Preservation of Visual Function in rd10 Retinas
Treated With hPI-PLGA-MS
The neuroprotective effect of hPI at the functional level was
evaluated by ERG in rd10 mice at P25, in dark- and light-adapted
conditions to measure rod- and cone-mediated vision, respec-
tively. In general, ERG waves in hPI-PLGA-MS–treated eyes (Fig. 3,
FIGURE 3. Preservation of ERG responses in hPI-treated rd10 eyes compared to control eyes. A representative example of the different ERG
responses recorded in hPI-treated eyes (hPI-MS) and contralateral control eyes (Control-MS) is shown. Electroretinographs were obtained at P25,
and the type of response recorded is indicated in each Figure.
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black lines) were better defined and greater in amplitude than in
the control ones (grey lines). The average b-mixed, b-cone, and
oscillatory potential (OP) amplitudes were significantly higher in
hPI-treated versus control retinas (Fig. 4). Electroretinography,
thus, confirmed a protective effect on a number of parameters of
visual function in hPI-PLGA-MS–treated retinas, consistent with
the partial preservation of the retinal structure seen in treated
eyes, as described above.
Attenuation of Cell Death in Organotypic Cultures
of hPI-Treated rd10 Retinas
We performed ex vivo studies to support that hPI had a
prosurvival effect on photoreceptor cells, as previously
suggested by a transgenic model expressing hPI in the
muscle.22 Retinal explants were prepared from rd10 mice at
P22, before the peak of cell death, and cultured in the absence
or presence of 108 M hPI. After 24 hours in culture, the
number of TUNEL-positive cells detected in the photoreceptor
layer was significantly lower in hPI-treated retinas compared to
untreated retinas (Fig. 5), indicating a protective effect of hPI
on photoreceptors.
Increase in Akt Phosphorylation in Organotypic
Cultures of hPI-Treated rd10 Retinas
The hPI signaling pathway was studied next in retinal explants.
P22 retinal explants were deprived from growth factors for 3
hours and then cultured in the absence or presence of 108 M
hPI for periods from 2 to 15 minutes. Phosphorylation of
AktThr308 was significantly increased by hPI at all tested time
points (Fig. 6). In contrast, there was no stimulation of ERK
phosphorylation (data not shown). Thus, these results
suggested that the neuroprotective effect of hPI is mediated
by the activation of the PI3-K/Akt signaling pathway. Since this
was observed in whole retina cultures, the activation of PI3-K/
Akt pathway may not be occurring exclusively in photorecep-
tor cells, and other cell types could be implicated in this
response, an aspect to be addressed in future studies.
Taken together, these data indicated that intravitreal
injection of PLGA microspheres was a feasible method for
the intraocular delivery of hPI, comparable to that previously
achieved using a systemic approach.22 Proinsulin, which was
able to activate the PI3-K/Akt pathway and to decrease
photoreceptor cell death, exerted a therapeutic effect by
preserving the ONL structure as well as the electroretino-
graphic function in the rd10 retina.
DISCUSSION
The present findings demonstrated that intravitreal administra-
tion of hPI formulated in biodegradable PLGA microspheres is a
feasible approach that displays cellular and electrophysiologic
neuroprotective effects in the rd10 mouse model.
The development of affordable mutation-specific therapy
for RP is extremely demanding, given that this retinal
dystrophy is caused by multiple diverse mutations at a large
number of genetic loci, each affecting a small number of
patients.32 Accordingly, the development of neuroprotective
strategies is a key area of research in the search for mutation-
independent therapies for RP.15,33 While gene augmentation or
replacement therapy has been successfully applied to patients
with Leber’s congenital amaurosis, the resulting improvement
in vision is transient, with photoreceptor degeneration
ultimately progressing over time.34,35 Neuroprotection could
constitute a valuable complementary therapy, and could be
applied before, in parallel with, or even after gene-specific
therapy to prolong vision.
In previous proof-of-concept studies in mice and rats, we
demonstrated that systemic elevation of hPI levels by trans-
genesis22 or AAV1 gene therapy24 delays photoreceptor
degeneration and prolongs visual function. An effective local
administration route, if feasible, should facilitate future clinical
trials. After testing several microsphere formulations of hPI, we
identified a formulation (FP50) that allowed an initial rapid
delivery of the active molecule, while levels of which were
sustainably released in vitro for over a month (Fig. 1B). In vivo,
intact hPI was detected in retinas from injected animals several
days after a single intravitreal injection (data not shown).
Moreover, the released hPI was biologically active and exerted
FIGURE 4. Average amplitudes of ERG waves in hPI-treated (hPI-MS) and
control (Control-MS) retinas. n¼ 15 to 17 mice for different responses.
Scale bars: mean 6 SEM. *P < 0.05, ***P < 0.005.
FIGURE 5. Photoreceptor cell death is ameliorated by hPI treatment in
explant cultures of rd10 retinas. Whole mount retinas from P22 rd10
mice were cultured for 24 hours in either defined medium ([A], n¼ 4)
or defined medium þ naked hPI 108 M ([B], n ¼ 5). TUNEL
subsequently was performed and the number of individual positive
cells in 4 areas of the retina was scored and plotted (C). Dots and
squares represent values for individual retinas; horizontal line
represents the mean value; *P < 0.05.
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a therapeutic effect by preserving nasal and central retinal ONL
structure as well as electroretinographic function, specifically
the OP, cone, and combined rod-cone responses. We speculate
that the ERG response may reflect a dual effect of hPI, that is, a
reduction in rod cell death, which leads to a structural
improvement in the retina, and exerts a neuroprotective effect
on synapses between rods and bipolar cells that improves their
functionality. The lack of an increase in the amplitude of the a-
mixed wave indicates that the electric response of these
photoreceptors is not increased after hPI treatment. However,
if there are more photoreceptors with less degenerated
synaptic terminals, one would expect improved function. At
low light intensity, this effect may not be sufficient to
significantly increase activation of bipolar cells. However, at
high light intensity, better preserved photoreceptors and their
synapses lead to the generation of a higher response in bipolar
cells (higher b-mixed wave). This more efficient activation of
bipolar cells, in turn, generates a stronger input in the
amacrine cells, thereby resulting in the significant increase in
OP after hPI treatment. This proposed explanation is support-
ed by our previous findings in another RP model, the P23H rat.
In that study, we found that administration of hPI via
intramuscular injection of an AAV vector preserved synaptic
connectivity between photoreceptors and bipolar and hori-
zontal cells.24
In recent years there has been much debate about the best
means of delivering exogenous proteins to the retina.36
Intraocular implants of encapsulated cells delivering CNTF
have been tested in animal models of retinal degeneration with
good tolerance (reviewed previously37). In fact, insulin
released from subconjunctivally implanted hydrogels reduced
retinal DNA fragmentation in diabetic rats and these implants
did not alter retinal histology over a 2-month period.38 Our
preliminary studies of local tolerance to PLGA-MS in rabbits
revealed no adverse effects (data not shown). Nonetheless,
further studies of the effects of intravitreal MS injections in
large animals (dogs or primates) will be necessary to assess
safety and efficacy of this approach. The biodegradable nature
of the PLGA-MS and the short half-life of proinsulin should
facilitate adequate dose-titration to ensure transient secondary
effects if caused by hPI.
The efficacy of intravitreal PLGA-MS treatment described
here in a model of RP represents a preliminary proof-of-
concept which supports that this is a potentially feasible
treatment strategy, eventually applicable in a variety of diseases
of the eye, including uveitis, macular edema, retinal detach-
ment, and age-related macular degeneration (reviewed previ-
ously30).
Our findings in explant cultures confirm a prosurvival effect
of hPI on photoreceptors, as previously proposed based on the
developmental effects of proinsulin. Whether the cells
responding to hPI are exclusively the photoreceptors, or there
is an additional effect on other retinal cell types that might be
beneficial as well for photoreceptor function still is unclear and
worth studying in the future. We have found in a previous
study that another member of the insulin related family of
proteins, IGF-I, has a complex effect on the rd10 retina,
involving polarization of microglia and attenuation of Mu¨ller
glial cell reactive gliosis.39,40 However, due to its high potency
stimulating proliferative pathways mediated by the IGF type I
receptor, IGF-I is not a good candidate for a neuroprotective
treatment. Paracrine effects may be important not only to
maintain the primary degenerating photoreceptor, the rods in
the case of the rd10 mutant mice, but also to rescue the
secondary death affecting the cones and additional retinal cells.
A similar type of neuroprotective effect also has been proposed
for the action of RdCVF in degenerated retina.19 Also a
panretinal preservation of photoreceptor nuclei was found in
FIGURE 6. Akt phosphorylation is stimulated by hPI treatment in explant
cultures of rd10 retinas. Whole mount retinas from P22 rd10 mice
were cultured for up to 15 minutes in either defined medium (Control)
or defined mediumþ naked 108 M hPI. Retina extracts were prepared
and immunoblotted with antibodies against pAktThr308 and total Akt
proteins. Representative blots are shown (A). The ratio of the
pAktThr308 and total Akt signals at 2 (B), 5 (C), and 15 (D) minutes
was obtained for individual retinas. Dots and squares represent values
for individual retinas; horizontal line represents the mean value; *P <
0.05, **P < 0.01.
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the rd10 mice, at P30, in a quantitative careful analysis after
treatment with tauroursodeoxycholic acid (TUDCA).41
While we did not specifically investigate the mechanism of
action of hPI as a prosurvival molecule, the presence of type A
insulin receptor (IR-A) mRNA was confirmed in wild type and
rd10 retinas (data not shown). This receptor has been found to
bind proinsulin and IGF-II with high affinity. In contrast,
proinsulin showed poor binding to the IR-B and it does not
bind IGF type I receptors.42 The proinsulin signaling through
IR-A also was supported by the phosphorylation of AktThr308,
residue phosphorylated upon insulin and growth factor
receptor stimulation. There is a large body of evidence
demonstrating the presence of insulin receptors in the retina
of different species.43 In bovine and human retina these
receptors are widely distributed in all retinal layers,44,45
meaning that most cell types are sensitive to proinsulin. The
presence and important role in neuroprotection of the insulin
receptors in rod photoreceptor cells has been demonstrated
clearly in a study using cell-specific receptor knockout mice.46
At least during retinal development, the prosurvival action
of proinsulin has been shown to involve the activation of the
PI3K pathway.47 Moreover, in the adult mouse retina Akt
activation in response to IR signaling is required to protect
against light damage.46 Regardless, further studies will be
necessary to elucidate the molecular mechanisms underlying
the observed prosurvival effect of hPI in the rd10 mouse.
Despite the several pending questions on proinsulin effect on
the dystrophic retina, our findings underscore the potential
value of MS-formulated hPI for a future RP therapy.
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